Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Lymphoma, Non-Hodgkin 2Lymphoma 2Thalassemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Kidney Transplantation 1Kidney Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Carcinoma, Renal Cell 1

Interventions

fludarabine 1Voriconazole 1Thalidomide 1Semen Analysis 1Remote Patient Monitoring 1Physical Examination 1Interviews as Topic 1Health Information Exchange 1Granulocyte Colony-Stimulating Factor 1Genetic Testing 1Fluconazole 1Exercise 1Dexamethasone 1Cyclophosphamide 1Complementary Therapies 1Cell- and Tissue-Based Therapy 1Busulfan 1Bone Marrow Transplantation 1Blood Specimen Collection 1Bismuth 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Hematologic Diseases × Alemtuzumab × Clear all
NCT00582894 2011-04-22

Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases

University of Oklahoma

Phase NA Completed
17 enrolled 9 charts
Other hematologic neoplasm

Hematologic Diseases, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡